MA43571A - Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations - Google Patents

Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations

Info

Publication number
MA43571A
MA43571A MA043571A MA43571A MA43571A MA 43571 A MA43571 A MA 43571A MA 043571 A MA043571 A MA 043571A MA 43571 A MA43571 A MA 43571A MA 43571 A MA43571 A MA 43571A
Authority
MA
Morocco
Prior art keywords
dkk2
cysteine
proteins containing
field rich
rich
Prior art date
Application number
MA043571A
Other languages
English (en)
Inventor
Joseph W Arndt
Andreas Lehmann
Brenda K Minesinger
Joshua Mugford
Nels E Pederson
R Blake Pepinsky
Richelle Sopko
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA43571A publication Critical patent/MA43571A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA043571A 2015-12-23 2016-12-16 Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations MA43571A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562387116P 2015-12-23 2015-12-23

Publications (1)

Publication Number Publication Date
MA43571A true MA43571A (fr) 2018-11-14

Family

ID=57794355

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043571A MA43571A (fr) 2015-12-23 2016-12-16 Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations

Country Status (4)

Country Link
US (1) US20200270335A1 (fr)
EP (1) EP3394265A1 (fr)
MA (1) MA43571A (fr)
WO (1) WO2017112549A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
CN101951954A (zh) * 2007-11-02 2011-01-19 诺瓦提斯公司 调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法
WO2010075194A1 (fr) 2008-12-22 2010-07-01 St. Jude Children's Research Hospital Expression procaryote de dkk soluble active
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
JP2013519392A (ja) 2010-02-16 2013-05-30 メディミューン,エルエルシー Hsa関連組成物および使用方法
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
MX353816B (es) 2011-05-05 2018-01-30 Albumedix As Variantes de albumina.
WO2016126054A1 (fr) * 2015-02-04 2016-08-11 (주)메드팩토 Composition pour prévenir ou traiter un trouble de l'érection comprenant une protéine dkk2 modifiée ou un gène pour celle-ci, et son procédé d'utilisation

Also Published As

Publication number Publication date
US20200270335A1 (en) 2020-08-27
EP3394265A1 (fr) 2018-10-31
WO2017112549A1 (fr) 2017-06-29

Similar Documents

Publication Publication Date Title
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
EP3581651A4 (fr) Anticorps anti-gprc5d et molécule le contenant
EP3344275A4 (fr) Macrocycles peptidomimétiques et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3471727A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3375796A4 (fr) Copolymère et composition le contenant
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
MA43551A (fr) Protéines immunomodulatrices à variants du ligand icos et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3710067A4 (fr) Domaine d contenant des polypeptides et utilisations associées
EP3294318A4 (fr) Macrocycles peptidomimétiques et leurs utilisations
EP3380100A4 (fr) Inhibiteurs de bromodomaines bivalents et leurs utilisations
EP2953457A4 (fr) Inhibiteurs d'erk et leurs utilisations
EP3307766A4 (fr) Protéine d'interleukine-7 modifiée et ses utilisations
EP3344624A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3349802A4 (fr) Dendrimères lipocationiques et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3364958A4 (fr) Modulateurs d'interaction sestrine-gator2 et leurs utilisations
EP3341007A4 (fr) Inhibiteurs de malt1 et leurs utilisations